Clinical Trial Update: A Study Comparing the Efficacy and Safety of CHF 1535 (BDP +FF) Inhalation Powder, Administered Via the NEXT Inhaler, Versus CHF 1535 (BDP +FF), Administered Via a pMDI, in Moderate to Severe Asthma [Phase 3]

View source ↗

Summary

A Phase 3 study comparing CHF 1535 (budesonide/formoterol) inhalation powder delivered via the NEXT inhaler to CHF 1535 (budesonide/formoterol) delivered by a p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF 1535 (BDP + FF) inhalation powder (budesonide/formoterol)
• CHF 1535 (BDP + FF) via pMDI (budesonide/formoterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 3 | Status: COMPLETED